12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation

Osteoporosis is a major health problem in the elderly. Almost every bone can fracture due to the increased bone fragility in osteoporosis, posing a major challenge to public health. 12-Deoxyphorbol-13-hexadecanoate (DHD), one of the main bioactive components of Stellera chamaejasme L. (Lang Du), is...

Full description

Bibliographic Details
Main Authors: Qi He, Junzheng Yang, Delong Chen, Yejia Li, Dawei Gong, Hui Ge, Zihao Wang, Haibin Wang, Peng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
12-deoxyphorbol-13-hexadecanoate
MAPK signaling pathway
Bone loss
ROS
NFATc1
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.899776/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.899776/full

Similar Items